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Purpose: The aim of this study was to investigate the susceptibility of Candida albicans and
Candida glabrata biofilm development, in their intermediate and maturation stages, to the
influence of silver nanoparticles (SN).
Methods: SN (5 nm) suspensions were synthesized via reduction of silver nitrate by a
solution of sodium citrate. These suspensions were used to treat Candida biofilms for five
hours, grown on acrylic surfaces for 24-h (intermediate stage) and 48-h (maturation stage),
and their efficacy was determined by total biomass (using crystal violet staining) and colony
forming units (CFUs) quantification.
Results: SN promoted significant reductions ( p < 0.05) in the total biomass and number of
CFUs of Candida biofilms, ranging from 23% to 51.5% and 0.63 to 1.59-log10, respectively.
Moreover, there were no significant differences in the total biofilm biomass ( p > 0.05), when
the different stages of biofilm development (24 or 48 h) were exposed to SN. Comparing the
number of CFUs between 24- and 48-h biofilms treated with SN, a significant difference
( p < 0.05) was found only for the C. albicans 324LA/94 strain.
Conclusions: In general, the intermediate and maturation stages of biofilm development do not
interfere in the susceptibility of C. albicans and C. glabrata biofilms to SN. These findings are
fundamental for the deployment of new therapies aimed at preventing denture stomatitis.
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Candida-associated denture stomatitis is a form of oral Candida
infection, covering areas of the mucosa which support the
upper denture [1]. This infection is prevalent among individu-
als under continuous use of drugs, with suppressed immune
systems, nutritional deficiencies and precarious denture
hygiene [2,3]. Moreover, it is associated with biofilm formation
by Candida species, of which Candida albicans and Candida
glabrata are the most abundant in the oral cavity [4].
The dynamic of Candida biofilm development on poly-
methylmethacrylate basically occurs in three stages: (i) early
(0–11 h), characterized by adhesion of blastospores to the
surface and formation of microcolonies [5]; (ii) intermediate
(12–30 h), represented by the proliferation of fungal cells (due
to cell budding) and their deposition on areas of irregularities,
and by the emergence of extracellular matrix production [5],
and (iii) maturation (31–72 h), in which the matrix production
increases with incubation time and the fungal colonies
become covered by this matrix, forming structures with
complex architectures [5]. An in vivo C. albicans biofilm denture
model (using rodents) has been developed to mimic human
denture stomatitis [6]. Not surprisingly, observation of Candida
biofilm formation using this in vivo model was comparable to
that noted in in vitro [5], showing the following stages of
development: 6 h, yeast cells adhered on the acrylic surface;
24 h, a confluent layer of cells covering the surface and the
start of extracellular matrix production; 48 h, a mature biofilm
comprising yeast, hyphae and host cells surrounded by the
extracellular matrix [6]. Biofilms are associated with antimi-
crobial resistance [7] and, therefore, infections related to them
are recalcitrant and tricky to treat [8].
Several studies [5,9,10] showed age-related differences of
biofilms in response to antimicrobial agents. Chandra et al. [5]
found that the minimum inhibitory concentrations (MICs) of
amphotericin B, nystatin, fluconazole, and chlorhexidine
were significantly higher for intermediate and mature C.
albicans biofilms than for earlier biofilms. Another study
revealed that mature bacteria biofilms were more resistant to
chlorhexidine preparations than young counterparts [10].
The presence of an extracellular matrix probably hinders the
penetration of drugs in mature biofilms, and contributes to
their resistance [11].
This fact has stimulated the use of nanotechnology to
generate new antifungal strategies to control Candida biofilm
formation in denture stomatitis. Currently, silver nanoparti-
cles (SN) have been tested against biofilms of Candida species
[12–17]. These nanoparticles, at concentrations ranging from
54 to 216 mg/mL, promoted significant reductions in the total
biomass and in the number of cultivable Candida biofilm cells
[12,14,16]. Previous results showed that SN combined with
either nystatin or chlorhexidine digluconate exhibited syner-
gistic antibiofilm activity dependent on the Candida species
and the drug concentrations used [17]. In addition, the
nanoparticle size and the type of stabilizing agent in the
silver colloidal nanoparticles did not interfere in their
antifungal activity against C. albicans and C. glabrata biofilms
[14]. The targets of antimicrobial action of SN are well
described in interesting studies [18–21].Although the literature displays encouraging findings
about the effect of SN against Candida biofilms at early stage
[12], an important point needs to be investigated: the
susceptibility of Candida biofilms at intermediate and matura-
tion stages of development to SN. The evaluation of the
physiological stages of biofilm development on the suscepti-
bility of Candida biofilms to SN is important for the knowledge
of their antibiofilm spectrum of action. Thus, the findings of
this study may contribute to broaden or restrict the use of SN
in future clinical applications, such as its direct incorporation
into acrylic resin or other polymers, adhesives, or varnishes,
and its use as a decontamination solution of complete
dentures. Therefore, the aim of this study was to investigate
the susceptibility of C. albicans and C. glabrata biofilm
development, in their intermediate and maturation stages,
to the influence of SN, through quantification of total biomass
and cultivable cells. The null hypothesis was that those two
stages of biofilm development would not differ in the
susceptibility to SN.
2. Materials and methods
2.1. Synthesis of silver colloidal nanoparticles
Silver nanoparticles (SN) were synthesized via reduction of
silver nitrate (AgNO3 – Merck KGaA, Darmstadt, Germany) at
5.0  103 mol/L by a solution of sodium citrate (Na3C6H5O7 –
Merck KGaA) at 0.3 mol/L [22]. A colloidal suspension was
formed when the solution turned yellow. Next, SN were
stabilized by adding a solution of ammonia (NH3 – Merck
KGaA) at 1.4 mol/L. These nanoparticles were characterized as
described previously [12], and the average size of SN obtained
was 5 nm.
2.2. Preparation of acrylic resin specimens
Acrylic resin specimens were used as substrates for biofilm
development. A stainless steel matrix with internal molds
was fixed with wax (Wilson, Sa˜o Paulo, Brazil) on a glass plate
with rough surface (to mimic the palatal roughness) and
invested with type III dental stone (Herodent, Petro´polis,
Brazil) into a denture flask. After the dental stone had set, the
flask was opened and the matrix molds and the glass plate
were cleansed with acetone. Powder and liquid denture resin
(QC20, Dentsply Ind. e Com. Ltd., Petro´polis, Brazil) were
proportioned, mixed, and pressed into the matrix molds and
polymerized according to the manufacturer’s instructions.
The acrylic specimens (10 mm  10 mm  3 mm) were
bench-cooled overnight before deflasking. Then, the excess
resin was removed with a bur (Maxi-Cut; Maillefer SA,
Ballaigues, Switzerland). The specimens were rinsed three
times with deionized water, dried at room temperature,
packaged in aluminum foil and autoclaved at 121 8C for
15 min [15].
2.3. Candida strains and culture conditions
Two reference strains from American Type Culture Collection
(ATCC), C. albicans (ATCC 10231) and C. glabrata (ATCC 90030),
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isolates were also examined, namely C. albicans 324LA/94
(obtained from the culture collection of Cardiff Dental School,
Cardiff, UK) and C. glabrata D1 (obtained from the Biofilm
Group of the Centre of Biological Engineering, University of
Minho, Braga, Portugal).
All strains were subcultured on Sabouraud dextrose agar
medium (SDA, Difco, Le Pont de Claix, France) at 37 8C for 24 h.
Then, yeast cells were inoculated in Sabouraud dextrose broth
(SDB; Difco) medium and incubated at 37 8C for 20–24 h under
agitation (120 rpm). Yeast cells were harvested by centrifuga-
tion after the incubation period (6500  g, for 5 min at 15 8C),
washed twice in phosphate buffered saline (PBS; pH 7, 0.1 M)
and the cellular concentration was adjusted to 1  107 cells/
mL in artificial saliva (AS) medium [12], using an improved
Neubauer chamber.
2.4. Biofilm development and treatment with SN
Candida biofilms were developed on acrylic resin specimens in
24-well microtiter plates (Costar, Tewksbury, USA) containing
1 mL of each Candida cell suspension (1  107 cells/mL in AS).
To form biofilms at intermediate stage (24-h biofilms), the
plates were incubated at 37 8C for 24 h under agitation
(120 rpm), while to generate biofilms at maturation stage
(48-h biofilms), the plates were incubated for 48 h under the
same conditions. For 24-h biofilms, after 12 h, 500 mL of AS
were withdrawn and an equal volume of fresh AS was added,
while for 48-h biofilms, the AS medium was renewed after
24 h. Following Candida biofilm development (24 and 48 h), the
specimens were washed once with 1 mL of PBS to remove non-
adherent cells. Next, 1 mL of 54 mg/mL [12,14,16] of SN diluted
in RPMI 1640 medium (Sigma–Aldrich, St. Louis, USA) was
added to the biofilm-containing wells. RPMI 1640 without SN
was added to the wells designated for controls. The plates
were then re-incubated under agitation in a shaker (120 rpm)
at 37 8C for 5 h.
2.5. Total biofilm biomass assay
The total biomass of Candida biofilms, after treatment, was
analyzed by using the crystal violet (CV) staining method
[12,15]. The medium was aspirated and the acrylic specimens
were gently washed with 1 mL of PBS to remove the planktonic
cells. Fixation was performed by adding 1 mL of 99% methanol
(Sigma–Aldrich) to the Candida biofilms and removing it after
15 min. Acrylic specimens were allowed to dry at room
temperature. Subsequently, 1 mL of CV stain (1%, v/v) (Merck
KGaA) was added into each well containing acrylic specimens
and incubated for 5 min. The excess of crystal violet was
withdrawn by washing the specimens with deionized water.
Crystal violet bound to the biofilms was detached using 1 mL
of acetic acid (33%, v/v) (Sigma–Aldrich). Finally, an aliquot
(200 mL) of the obtained solution was transferred to a 96-well
plate and the absorbance was then measured in a microtiter
plate reader (Eon Microplate Spectrophotometer; Bio Tek,
Winooski, USA) at 570 nm and standardized in relation to the
area of acrylic specimens (Abs/cm2). The assays were
performed, independently and in triplicate, at least three
times.2.6. Quantification of biofilm cells assay
The quantification of Candida cultivable cells from biofilms
treated with SN was carried out by counting colony-forming
units (CFUs). For this, the acrylic specimens were washed with
PBS, sonicated (30 s at 40 W) and vortexed (5 min) into falcon
tubes containing 1 mL of PBS. Each biofilm cell suspension was
serially diluted in PBS and plated on SDA. After incubation at
37 8C for 24 h, the total number of CFUs per unit area
(Log10 CFU/cm
2) of acrylic specimens was enumerated. The
experiments were performed, independently and in triplicate,
at least three times.
2.7. Statistical analysis
The normality of the data was verified using the Shapiro–Wilk
test. Afterwards, parametric statistical analysis was per-
formed for each test using two-way ANOVA, and post hoc
Holm–Sidak test using SigmaPlot 12.0 software. Treatment
with and without SN, and the biofilm stage (intermediate and
maturation), were considered as variation factors. All tests
were performed with a confidence level of 95%.
3. Results
In accordance with Fig. 1, it was observed that the 24-h
biofilms of C. albicans ATCC 10231, C. albicans 324LA/94, C.
glabrata ATCC 90030 and C. glabrata D1 treated during 5 h with
SN at a concentration of 54 mg/mL showed significant
reductions in the total biomass of 23 ( p = 0.002), 22.9
( p < 0.001), 42.9 ( p < 0.001) and 27.7% ( p < 0.001), respectively,
compared to their respective controls. For 48-h biofilms (Fig. 1),
C. albicans ATCC 10231, C. albicans 324LA/94, C. glabrata ATCC
90030 and C. glabrata D1 showed significant reductions in the
total biomass of 47.2 ( p < 0.001), 35.8 ( p < 0.001), 51.5
( p < 0.001) and 36.8% ( p < 0.001), respectively, compared to
their respective controls. Although untreated 48-h biofilms
(controls) of C. albicans ATCC 10231, C. albicans 324LA/94 and C.
glabrata ATCC 90030 generated a significantly ( p < 0.05) higher
biomass than 24-h counterparts, comparisons between 24-
and 48-h biofilms treated with SN did not show significant
differences in reducing total biomass ( p > 0.05), for all strains.
Thus, the stages of biofilm development tested (intermediate
and maturation) did not interfere with the susceptibility of
Candida biofilms to SN.
Concerning the effect of SN on the biofilm cultivable cells
(Fig. 2), 24-h biofilms of C. albicans ATCC 10231, C. albicans
324LA/94, C. glabrata ATCC 90030 and C. glabrata D1 treated for
5 h with SN showed decreases in the number of CFUs of,
respectively, 0.27 ( p > 0.05), 0.96 ( p = 0.002), 1.59 ( p < 0.001)
and 1.03-log10 ( p = 0.005), compared to the control groups. For
48-h biofilms (Fig. 2), the treatment with SN promoted a
significant decrease in the number of CFUs for C. albicans ATCC
10231 (reduction of 0.63-log10, p = 0.035), C. albicans 324LA/94
(reduction of 1.44-log10, p < 0.001) and C. glabrata ATCC 90030
(reduction of 1.27-log10, p = 0.005), compared to the controls.
Additionally, comparing the number of CFUs between 24- and
48-h biofilms treated with SN, significant differences were
found ( p = 0.021) only for C. albicans 324LA/94, with higher
Fig. 2 – Logarithm of colony forming units per cm2 obtained for Candida biofilms at intermediate (24-h biofilm) and
maturation (48-h biofilm) stages of development, after treatment with silver nanoparticles (SN) at 54 mg/mL during 5 h. Error
bars indicate the standard deviations of the means. (*) Denote statistical difference between the groups by using two-way
ANOVA and post hoc Holm–Sidak test with a confidence level of 95%.
Fig. 1 – Absorbance values per cm2 obtained with crystal violet staining assay for Candida biofilms at intermediate (24-h
biofilm) and maturation (48-h biofilm) stages of development, after treatment with silver nanoparticles (SN) at 54 mg/mL
during 5 h. Error bars indicate the standard deviations of the means. (*) Denote statistical difference between the groups by
using two-way ANOVA and post hoc Holm–Sidak test with a confidence level of 95%.
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For the other strains, these comparisons did not show
significant differences ( p > 0.05), and the stages of biofilm
development tested did not reveal a significant influence on
the susceptibility to SN.
4. Discussion
This study was carried out with 24-h and 48-h biofilms to
encompass, respectively, the intermediate and the maturation
stages of Candida species biofilms on acrylic strips. The effect
of SN on Candida biofilms at early stage of development was
demonstrated in a previous study [12]. Considering the data
obtained in this study, it was possible to partially accept thenull hypothesis since the two stages of Candida biofilm
development only differed in susceptibility to SN for C. albicans
324LA/94 viable cells.
In general, mature biofilms are recalcitrant and more
tolerant to antimicrobials. Some mechanisms have been
proposed to explain their resistance, namely: decreased
metabolic activity; altered gene expression; protective
extracellular matrix, which may hamper the diffusion of
drugs; and presence of persistent cells [23]. For instance,
Anwar et al. [24] found that Staphylococcus aureus biofilms
formed during a 4-day period exhibited higher decrease in
viable cell counts when treated with tobramycin and
cephalexin than 13-day-old biofilms. These authors used a
variation between young and mature biofilms more marked
(9 days) than that used in the present study (1 day). This
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studies are distinct.
The intermediate stage of Candida biofilms is characterized
by the emergence of extracellular matrix covering the fungal
microcolonies, while in mature biofilms higher amounts of
extracellular material and fungal cells completely involved by
this material are evident [5,6]. Comparing the total biomass
between 24- and 48-h untreated biofilms (controls), the results
in Fig. 1 showed significant differences for C. albicans ATCC
10231, C. albicans 324LA/94 and C. glabrata ATCC 90030, with
higher values for the mature biofilms. On the other hand, the
proportions of cultivable cells (Fig. 2) in mature (48 h)
untreated biofilms were similar to those of young counterparts
(24 h). All these results indicate that the differences between
24- and 48-h biofilm biomasses occur exclusively due to
increased production of extracellular matrix by 48-h untreated
biofilms.
Interestingly, even with this increased matrix production
by 48-h untreated biofilms, it was not possible to find
differences in the susceptibility to SN between 24- and 48-h
biofilms (Fig. 1). The treatment with SN probably produces a
plateau of biomass accumulation regardless of the stage of
biofilm development. Regarding cell viability (Fig. 2), the
results showed the same trend, except for C. albicans 324LA/94.
For this strain, curiously, 48-h biofilm was more susceptible to
SN than 24-h biofilm. The reason for this phenomenon is
unknown. However, it is believed that the observed pattern is
due to the low variability of the data obtained for the 48-h
treated biofilm compared to the variability of the data for the
24-h treated biofilm.
Similar results were found by Chandra et al. [5]. These
authors determined the MICs of amphotericin B, nystatin,
fluconazole and chlorhexidine for early, intermediate, and
mature C. albicans biofilms. They observed that during early
biofilm stage the MICs were 0.5, 1, 8, and 16 mg/mL for
amphotericin B, fluconazole, nystatin and chlorhexidine,
respectively. However, after 24 and 48 h (intermediate and
maturation stages), the MIC values did not differ and reached
values of 8, 128, 16, and 256 mg/mL for amphotericin B,
fluconazole, nystatin and chlorhexidine, respectively.
The highlight of the present study’s findings is that, in
general, mature C. albicans and C. glabrata biofilms (48 h) were
not more tolerant against SN than intermediate biofilms of
these Candida species. This fact may indicate the use of SN to,
both prevent biofilms to reaching more advanced stages of
development, and combating preformed biofilms already in
the stage of maturation. Consequently, the same SN concen-
tration might have a broader clinical applicability at prevent-
ing denture stomatitis. We recommend further assays testing
antifungals against different stages of biofilms, since it could
have an impact on time and material consumption in research
involving Candida biofilms. Thus, a stage of biofilm develop-
ment of 24 h may serve as a standard for future in vitro
susceptibility tests.
Our previous work showed that SN had a more pronounced
effect against adhered cells (early stage of biofilm formation)
of the same strains of C. albicans and C. glabrata, achieving
reductions around 85–90% in the total biomass and 6.5-log10 in
the number of CFUs [12]. The early stage is characterized by
lower amounts of cells and in a metabolically excited state[25]. Taken together, it may have increased the efficacy of the
SN against Candida species since their paths were ‘‘cleaner’’ to
reach these targets.
Regarding the biofilm quantification results, it should be
emphasized that CV staining assay does not allow differenti-
ation between living and dead cells, so it was used as a
complement trial to CFU enumeration. In general, significant
reductions were observed in the total biomass and in the
number of CFUs ranging from 23% to 51.5% (Fig. 1) and 0.63 to
1.59-log10 (Fig. 2), respectively. This highlights the effect of SN
in the biofilm matrix and also in their cells. SN may have
dissolved part of the extracellular matrix material, diffused
inside the biofilm matrix through the pores and reached the
cells in the deeper layers [26]. When in contact with the fungal
cells, these nanoparticles preferably attack their membranes,
causing disruption of membrane potential and subsequent
cell death [19]. Moreover, SN may inhibit respiratory chain
enzymes and interact with the DNA of microorganisms,
preventing cell reproduction [18,20,21].
Furthermore, the silver concentration tested in the present
study (54 mg/mL) can be considered low, when compared with
the concentrations of conventional antifungal drugs used in
some studies. Fonseca et al. [27] evaluated the fungicidal
activity of fluconazole against 24-h C. glabrata biofilms and
found that this agent, at concentrations ranging from 50 to
1250 mg/mL, was ineffective in reducing total biofilm biomass
and number of CFUs. In the study of Tobudic et al. [28],
posaconazole at concentrations of 2 and 256 mg/mL also was
ineffective in reducing the number of CFUs of C. albicans
biofilms. Vandenbosch et al. [29] verified that the treatment
with miconazole at 2081 mg/mL resulted in a significant
reduction (ranging from 89.3% to 99.1%) in the number of
CFUs for C. albicans, C. glabrata, Candida Krusei, Candida
parapsilosis and Candida tropicalis biofilms.
Although SN have been studied as a possible antifungal
agent in order to prevent denture stomatitis, the good
mechanical hygiene [30] and removal of dentures during
nocturnal sleep should not be neglected for maintenance of a
healthy mucosa. Our research group is working to assess the
most advantageous formula of SN against Candida biofilms
without damage to human cells. In the future, these
nanoparticles might be incorporated in denture base resins,
with safety for human health, or used as a solution for denture
decontamination. Studies focused on preventing denture
stomatitis are very important due to the increase in the
elderly population and complete denture wearers, mainly in
developing countries [31].
Finally, the understanding of the relationship between the
physiological stages of biofilm development and the efficacy of
SN may provide insights for the conception of new therapies
targeted to control Candida infections. Further, results about
the antibiofilm effect of SN are promising and should inspire in
situ and in vivo investigations with formulations or materials
based on SN to manage Candida-associated denture stomatitis.
5. Conclusions
Within the limitations of the present study, it was concluded
that:
j o u r n a l o f p r o s t h o d o n t i c r e s e a r c h 5 9 ( 2 0 1 5 ) 4 2 – 4 8 47 The intermediate and maturation stages of biofilm develop-
ment do not interfere in the susceptibility of C. albicans and
C. glabrata biofilms to SN regarding total biomass and
cultivable cells, except for C. albicans 324LA/94 CFU enumer-
ation.
 The knowledge of the relationship between the stages of
biofilm development and the effect of SN is crucial for the
deployment of new therapies aimed at preventing and
controlling of Candida-associated denture stomatitis.
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